These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 24419749)

  • 1. Advances in kinase inhibition: treating rheumatic diseases and beyond.
    Gadina M
    Curr Opin Rheumatol; 2014 Mar; 26(2):237-43. PubMed ID: 24419749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinases to jakinibs: from basic insights to clinical practice.
    Gadina M; Le MT; Schwartz DM; Silvennoinen O; Nakayamada S; Yamaoka K; O'Shea JJ
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i4-i16. PubMed ID: 30806710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases.
    Damsky W; Peterson D; Ramseier J; Al-Bawardy B; Chun H; Proctor D; Strand V; Flavell RA; King B
    J Allergy Clin Immunol; 2021 Mar; 147(3):814-826. PubMed ID: 33129886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinases: an ideal target for the treatment of autoimmune diseases.
    Gadina M
    J Investig Dermatol Symp Proc; 2013 Dec; 16(1):S70-2. PubMed ID: 24326567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
    Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
    J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Jakpot! New small molecules in autoimmune and inflammatory diseases.
    Ghoreschi K; Gadina M
    Exp Dermatol; 2014 Jan; 23(1):7-11. PubMed ID: 24131352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.
    Patterson H; Nibbs R; McInnes I; Siebert S
    Clin Exp Immunol; 2014 Apr; 176(1):1-10. PubMed ID: 24313320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging safety profile of JAK inhibitors in rheumatic disease.
    Winthrop KL
    Nat Rev Rheumatol; 2017 Apr; 13(4):234-243. PubMed ID: 28250461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.
    Clark JD; Flanagan ME; Telliez JB
    J Med Chem; 2014 Jun; 57(12):5023-38. PubMed ID: 24417533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs.
    Cornez I; Yajnanarayana SP; Wolf AM; Wolf D
    Mol Cell Endocrinol; 2017 Aug; 451():88-96. PubMed ID: 28131742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.
    Schwartz DM; Bonelli M; Gadina M; O'Shea JJ
    Nat Rev Rheumatol; 2016 Jan; 12(1):25-36. PubMed ID: 26633291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.
    Kontzias A; Kotlyar A; Laurence A; Changelian P; O'Shea JJ
    Curr Opin Pharmacol; 2012 Aug; 12(4):464-70. PubMed ID: 22819198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
    Howell MD; Kuo FI; Smith PA
    Front Immunol; 2019; 10():2342. PubMed ID: 31649667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK inhibitors for the treatment of autoimmune and inflammatory diseases.
    Jamilloux Y; El Jammal T; Vuitton L; Gerfaud-Valentin M; Kerever S; Sève P
    Autoimmun Rev; 2019 Nov; 18(11):102390. PubMed ID: 31520803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinase inhibitors: a new approach to rheumatoid arthritis treatment.
    Cohen S; Fleischmann R
    Curr Opin Rheumatol; 2010 May; 22(3):330-5. PubMed ID: 20164774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.
    Flamant M; Rigaill J; Paul S; Roblin X
    Drugs; 2017 Jul; 77(10):1057-1068. PubMed ID: 28523588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New kinase inhibitors].
    Rubbert-Roth A
    Z Rheumatol; 2012 Aug; 71(6):479-84. PubMed ID: 22777068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders.
    Furumoto Y; Gadina M
    BioDrugs; 2013 Oct; 27(5):431-8. PubMed ID: 23743669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma.
    Zak M; Dengler HS; Rajapaksa NS
    Bioorg Med Chem Lett; 2019 Oct; 29(20):126658. PubMed ID: 31522830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases.
    Szilveszter KP; Németh T; Mócsai A
    Front Immunol; 2019; 10():1862. PubMed ID: 31447854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.